A new study shows how resistance to a promising targeted drug develops in patients with a rare, lethal cancer of the bile ducts called cholangiocarcinoma.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/01/200114123518.htm
No comments:
Post a Comment